The FDA recommended advancement for a new drug application submitted by a company.
2 reports, 1 independent
Updated Jul 15
Gone quiet
- Reports
- 2
- Developments
- 3
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA recommended advancement for a new drug application submitted by a company.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Revelation Biosciences is submitting successful Phase 2/3 trial data for a proprietary drug candidate to the U.S. Food and Drug Administration.Sub-event
- Century is seeking FDA authorization for a new product.Sub-event
FDA recommended advancement for a new drug application.1 source
Keep exploring
The entities involved
Related events
- FDA approval expands patient access to therapies for ACCORD.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.
- Merck announced on September 3, 2025, that it is seeking potential approval for new drugs from the FDA.
- Generic medicine services are seeking approval for launch from the FDA.
Coverage
Newest first; wire copies grouped- GlobeNewswireSELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML and Receives FDA Guidance to Advance into First-Line Therapy Study The Trial Exceeded Target Overall Response Rate (ORR) of 20
- Unknown outlet